News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
2024 full-year revenue guidance raised by US$ 2 billion
Highly effective preservation solutions ensuring the safety and protection of personal care products
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Meningitis still affects more than 2.5 million people globally each year
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
